Resource impact statement
NICE has recommended empagliflozin within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 56.6 million people).
This is because the technology is a further treatment option, is available at the same price as dapagliflozin and clinical outcomes are expected to be similar.
The list price of 10 mg empagliflozin is £36.59 per 28-tablet pack (excluding VAT; BNF online accessed September 2023). The annual treatment cost is around £477.
This statement is supported by a resource impact template which may be used to calculate the resource impact of implementing the guidance by amending the variables via local input.
This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
This page was last updated: